Clinical trials: RSV
Respiratory Syncytial Virus Infection Prevention
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
This is a randomized, observer-blinded, placebo-controlled Phase Ⅱ clinical trial to evaluate the immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.
- Trial name
- NCT07208461
- Testing
- Low dose antigen of LYB005 without A01B adjuvant, Low dose antigen of LYB005 with A01B adjuvant, Middle dose antigen of LYB005 without A01B adjuvant
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Respiratory Syncytial Virus
Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above
The primary objective of this study is to evaluate the immunogenicity and safety of a single injection of two dose levels of ABO1105 in adults aged 50 years or above.
- Trial name
- NCT07289542
- Testing
- ABO1105
- Where
- China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Respiratory Syncytial Virus Infections
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the investigational GSK RSV vaccine in pregnant women aged 18 to 40 years and infants born to the vaccinated women
- Trial name
- NCT03191383
- Testing
- RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3
- Where
- 12 sites in United States, Finland and 1 more
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension
This trial is a multi dose, randomized, double-blind, placebo-controlled, single center Phase I clinical study. The purpose of this study is to evaluate the safety, tolerability, and PK characteristics of Deuteromide Hydrobromide…
- Trial name
- NCT06328400
- Testing
- Deuremidevir Hydrobromide for Suspension
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Respiratory Syncytial Virus (RSV)
A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.
Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness, where medical help is needed. RSV can lead to airway diseases in all ages. Vaccines help your body make antibodies.
- Trial name
- Amélie (NCT06473519)
- Testing
- RSVpreF MDV, RSVpreF SDV
- Where
- 6 sites in United States
- Volunteers
- 453 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection
The primary objective is to evaluate the anti-viral effect and safety of different doses of inhaled ALX-0171 in subjects hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection (RSV LRTI).
- Trial name
- Respire (NCT02979431)
- Testing
- ALX-0171 3.0 mg/kg, ALX-0171 6.0 mg/kg, ALX-0171 9.0 mg/kg
- Where
- 74 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 180 people
- Sponsor
- Ablynx, a Sanofi company
Respiratory Syncytial Virus Infections
RV568 - Viral Challenge With RSV
RV568 is being developed for the treatment of diseases such as asthma, COPD and allergic rhinitis (e.g. hayfever). The main aim of this study is to investigate whether RV568 is effective in reducing the inflammation caused by…
- Trial name
- NCT01230645
- Testing
- RV568
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Respiratory Syncytial Virus Infections
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy late preterm and term infants who are 35 weeks or greater gestational age and…
- Trial name
- MELODY (NCT03979313)
- Testing
- MEDI8897
- Where
- 198 sites in United States, Argentina and 29 more
- Volunteers
- 3,012 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
RSV Infection
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the…
- Trial name
- NCT06866405
- Testing
- RSVpreF
- Where
- 97 sites in United States, Argentina and 2 more
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.
The purpose of the AcRIS study is to obtain data to characterize the relationship between symptoms and voice features for (reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome…
- Trial name
- NCT04748445
- Testing
- SARS-CoV-2/Influenza/RSV RT-PCR
- Where
- United States
- Volunteers
- 9,151 people, healthy volunteers welcome
- Sponsor
- Pfizer
RSV Infection
A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV
This is a randomized, double-blind, placebo-controlled Phase Ib/IIa study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of XW001 inhalation in children with RSV infection in China
- Trial name
- NCT05779995
- Testing
- XW001
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Influenza A, Influenza B
Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer
The objective of this study is to evaluate the clinical sensitivity and specificity of the Liat™ Influenza A/B \& RSV Assay and the Liat™ Influenza A/B Assay when used on the Liat Analyzer to detect the presence or absence of…
- Conditions
- Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT02067286
- Where
- 8 sites in United States
- Volunteers
- 1,642 people
- Sponsor
- IQuum, Inc.
Healthy
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
Primary objective of this study is to describe the safety and tolerability of multiple doses of MEDI-534 in children 6 to less than (<) 24 months of age and in infants 2 months of age.
- Trial name
- NCT00686075
- Testing
- MEDI-534, Cohort 1, MEDI-534, Cohort 2, MEDI-534, Cohort 3
- Where
- 100 sites in United States, Australia and 7 more
- Volunteers
- 1,338 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza A, Influenza Type B
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
The goal of this observational study is to compare the FINDER FLU A/B, RSV, SARS-CoV-2 Test to an FDA-cleared device. The study will utilize prospectively collected de-identified nasopharyngeal samples obtained from both…
- Conditions
- Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
- Trial name
- NCT05928507
- Testing
- Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Baebies, Inc.
Upper Respiratory Tract Infection, Lower Respiratory Tract Infection
RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study (ADMA 001) is to evaluate the safety and efficacy of RI-001 for the prevention of lower…
- Trial name
- NCT00632463
- Testing
- RI-001
- Where
- 19 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- ADMA Biologics, Inc.
Healthy Participants
A Study of IVX-A12 in Adults Participants
The primary purpose of this study is to assess the immunogenicity and safety of IVX-A12 in adults 60 years of age and older.
- Trial name
- NCT06481579
- Testing
- IVX-A12, Licensed RSV Vaccine
- Where
- 5 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Icosavax, Inc.
Respiratory Syncytial Virus Infections
Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults
The main aims of the study are to assess the safety, tolerability, pharmacokinetics and food effects of RV299 compared to Placebo in healthy adult participants.
- Trial name
- NCT06033612
- Testing
- RV299, Midazolam
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus (RSV)
Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women
A Phase 1 study to evaluate safety, tolerability and immunogenicity a RSV vaccine in healthy women 18 to 49 years of age
- Trial name
- RSVVaccine (NCT07492706)
- Testing
- MKK900 60 µg, MKK900 120 µg, ABRYSVO®
- Where
- 2 sites in Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Healthy Participants
A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone.
- Trial name
- NCT05886777
- Testing
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF
- Where
- 37 sites in United States
- Volunteers
- 1,142 people, healthy volunteers welcome
- Sponsor
- Pfizer
RSV Infection, Human Metapneumovirus Infection
Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
This phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Parts 1 and 2) or Placebo (Part 3).
- Conditions
- RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
- Trial name
- NCT06984094
- Testing
- SCB-1019T, SCB-1022, SCB-1033
- Where
- 3 sites in Australia
- Volunteers
- 612 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty